{"id":"W2029587541","doi":"10.1111/j.1398-9995.2004.00772.x","title":"Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","year":2004,"lang":"en","type":"article","venue":"Allergy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1118,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Research in Astrophysics of Québec","funders":"","keywords":"Omalizumab; Medicine; Asthma; Exacerbation; Placebo; Adverse effect; Population; Internal medicine; Pediatrics; Incidence (geometry); Randomized controlled trial; Asthma exacerbations; Intensive care medicine; Immunoglobulin E; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001478248,0.0004377979,0.00158546,0.0002522302,0.0001411199,0.0005886756,0.0004210359,0.0008256221,0.001730338],"category_scores_gemma":[0.001274368,0.0002105929,0.001078344,0.0001697626,0.0003817544,0.0003575564,0.0003420969,0.001275416,0.0002092978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003984865,"about_ca_system_score_gemma":0.0004209827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003385554,"about_ca_topic_score_gemma":0.001195733,"domain_scores_codex":[0.9994867,0.0002597663,0.00003539486,0.00006506128,0.00007359764,0.0000794657],"domain_scores_gemma":[0.9991376,0.000326341,0.0002627579,0.00004638951,0.00003089338,0.0001960534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7973078,0.01235978,0.01511724,0.001030461,0.001791326,0.000171685,0.0001416486,0.0007422736,0.02001612,0.0001390276,0.001103311,0.1500794],"study_design_scores_gemma":[0.5303361,0.356059,0.1018601,0.000200825,0.003054959,0.00045792,0.00007165741,0.001588154,0.004018443,0.0001957058,0.002109977,0.00004722649],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944195,0.004424527,0.0001063725,0.0002852646,0.00004736661,0.0001680944,0.0001086182,0.00001674428,0.0004233224],"genre_scores_gemma":[0.9965287,0.001656148,0.0006054714,0.0003316969,0.0001262456,0.0001578989,0.0002135319,0.000004326861,0.0003760009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001730338,"threshold_uncertainty_score":0.007817864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01912305832587868,"score_gpt":0.2339531596340917,"score_spread":0.2148301013082131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}